2026sept
VRTX Sep 2026 · Sell
Vertex Pharmaceuticals Incorporated commands an undisputed commercial monopoly in cystic fibrosis therapies and is expanding into acute pain and gene editing, but its current market valuation of $526.19 trades at an unsustainable 57.1% premium to our fundamental fair value midpoint of $334.95.Latest published research · analyzed 2026-09-26 · current · sources stale